InvestSMART

IDT Australia Limited (ASX:IDT)

ALERT: Price-sensitive ASX Announcement for IDT
Current share price for IDT : $0.031 -0.012 (-27.91%)+
Announcement
Release
18 Feb 2026 10:14AM
Price at Release
$0.043
Full Release
download
Summary
The 1HFY26 results for IDT Australia Limited highlight the company's strategic realignment and efforts under new leadership to address operational and financial challenges. Key performances include a promising earnings recovery marked by a $2.3 million increase in EBITDA, primarily driven by strong growth in the API Manufacturing and Specialty Orals businesses. The company achieved significant cost optimizations, doubling its annualized cost savings target to $2 million. Revenue from the three core business verticals increased by 20.3%, reaching $8.4 million. Operating expenses were successfully reduced, attributed to resource reallocation and early benefits from automation. Looking forward, IDT focuses on leveraging its position as Australia’s first mRNA vaccine manufacturer to capitalize on growth opportunities in the mRNA and radiopharmaceutical markets. The strategic focus remains on high-margin, high-demand segments to ensure continued profitability and operational efficiency.
Key Points
  • Strategic realignment under new leadership led to earnings recovery with an increase in EBITDA.
  • Revenue growth primarily driven by the API Manufacturing and Specialty Orals businesses.
  • Annualized cost savings target increased to $2M from the original $1M.
  • Operating revenue from three business verticals rose to $8.4M, marking a 20.3% increase from the previous comparative period.
  • Operating expenses reduced due to resource reallocation and automation benefits.
  • A positive outlook for the full year with further gains expected from strategic initiatives.
  • IDT is Australia's first mRNA vaccine manufacturer with significant growth in mRNA and radiopharmaceutical sectors.
  • API Manufacturing reestablished as the foundation for growth and targeting follow-on contracts.
  • Strategic focus on high-demand areas like radiopharmaceuticals and mRNA innovations.
  • Operating leverage benefits expected from streamlined operations and resource reallocations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.